Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 9
Submit an article Journal homepage
58
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Survival gains in myelodysplastic syndromes following a decade of the modern treatment paradigm

Diego Adrianzen-Herreraa Department of Medicine, Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0168-2165View further author information
ORCID Icon,
Andrew D. Sparksb Biomedical Statistics Research Core, Larner College of Medicine at the University of Vermont, Burlington, VT, USAView further author information
,
Akshee Batraa Department of Medicine, Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USAView further author information
&
Neil A. Zakaia Department of Medicine, Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USA;c Department of Pathology and Laboratory Medicine, Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USAView further author information
Pages 1574-1578 | Received 03 Nov 2022, Accepted 25 May 2023, Published online: 10 Jun 2023

References

  • List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549–557.
  • Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20(10):2429–2440.
  • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803.
  • Saber W, Horowitz MM. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology Am Soc Hematol Educ Program. 2016;2016(1):478–484.
  • Schrijvers D, De Samblanx H, Roila F, et al. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for Use. Ann Oncol. 2010;21(Suppl. 5):v244–v247.
  • List AF, Bennett JM, Sekeres MA, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2014;28(5):1033–1040.
  • Bernal T, Martinez-Camblor P, Sanchez-Garcia J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish Registry. Leukemia. 2015;29(9):1875–1881.
  • Bonadies N, Feller A, Rovo A, et al. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. Cancer Epidemiol. 2017;46:85–92.
  • Al-Kali A, Zblewski D, Foran JM, et al. Outcome of myelodysplastic syndromes over time in the United States: a National Cancer Data Base Study from 2004–2013. Mayo Clin Proc. 2019;94(8):1467–1474.
  • Frosch ZA, Abel GA. Assessing quality of care for the myelodysplastic syndromes. Curr Hematol Malig Rep. 2016;11(6):402–407.
  • Mariotto AB, Noone AM, Howlader N, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145–186.
  • World Health Organization. International Classification of Diseases for Oncology (ICD-O). 3rd ed.; 2013. Available from: http://www.who.int/iris/handle/10665/96612
  • Surveillance Research Program. National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 8.9.3; 2007, https://seer.cancer.gov/data/citation.html
  • Brunner AM, Blonquist TM, Hobbs GS, et al. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017;1(23):2032–2040.
  • Buckstein R, Chodirker L, Mozessohn L, et al. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry. Leuk Lymphoma. 2022;63(13):1–10.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.